CHG-2021-0132

Analytical Method Change for Respiralimab. New Dosage Strength for Respiralimab — major revision. Impacts 1 markets and 1 variations.

Change Number
CHG-2021-0132
Type
Analytical Method Change
Product
Respiralimab
Status
Failed
Owner
Nadia Petrova
Initiated
2023-08-12
Description

New Dosage Strength for Respiralimab — major revision

Impacted Markets (1)
CH — Switzerland
Impacted Modules
3.2.P3.2.P.3
Linked Variations (0)
Variation #TypeApplicationStatusSubmittedApproved